Bharat BioTech s Covaxin gets expert panel s recommendation for emergency use, DCGI to take final call
A govt-appointed expert panel has recommended that Bharat BioTech s Covid-19 vaccine, Covaxin, should be given restricted emergency use in India.
advertisement
Covaxin is being indigenously developed by Bharat Biotech in India. (File photo)
Bharat BioTech s Covid-19 vaccine, Covaxin, has become the second vaccine to secure recommendation for restricted emergency use from a government-appointed expert panel in India. This comes a day after the panel made a similar recommendation for Covishield, the vaccine developed by Oxford University and AstraZenca.
An expert panel of the Central Drugs Standard Control Organisation (CDSCO) on Saturday recommended Covaxin should be granted restricted emergency use in India.
As it came closer to the roll-out of the first COVID-19 vaccine, India held a dry run by all states and union territories on Saturday in preparation for a massive vaccination drive, with Health Minister Harsh Vardhan appealing to people not to be misguided by rumours and disinformation regarding the safety and efficacy of coronavirus vaccine. Vardhan said that free vaccine would be provided in the first phase to the most prioritised beneficiaries, including one crore healthcare and two crore frontline workers. He said the details of how 27 crore priority beneficiaries those above 50 years of age and those below it having comorbidities would be vaccinated until July were being finalised.
Updated Jan 02, 2021 | 12:32 IST The announcement comes amid a dry run for coronavirus vaccination is underway in all the States and Union Territories. Union Health Minister Harsh Vardhan | Photo Credit: PTI
Key Highlights
Not just in Delhi, it will be free across the country, says Union Health Minister Harsh Vardhan
Meanwhile, a dry run for coronavirus vaccination is underway in all the States and Union Territories
New Delhi: Union Health Minister Harsh Vardhan on Saturday said that the Covid-19 vaccine will be provided free of cost across the country. The announcement comes amid a dry run for coronavirus vaccination is underway in all the States and Union Territories.
India tests vaccine delivery system with nationwide trial - World News castanet.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from castanet.net Daily Mail and Mail on Sunday newspapers.
Delhi has completed a full dry run as India prepares to deliver 50million doses of the Oxford vaccine that it has manufactured and stockpiled.
Experts at the country s drugs regulator have recommended for emergency use two coronavirus vaccines, one developed by AstraZeneca and Oxford University and the other backed by a state-run institute, the government said today.
SII, the world s biggest producer of vaccines, has already stockpiled about 50million doses of the AstraZeneca/Oxford shot, which will be sold to the government at about 250 rupees (£2.50) per dose and 1,000 rupees on the private market.
India s government plans to inoculate 300million people in total in the first phase of the vaccination programme, which will include healthcare and front-line workers, police and military troops and over-50s with underlying medical conditions.